The HIT-TB project is a collaboration between the FNIH and the National Institute of Allergy and Infectious Diseases, along with academic institutions in the United Kingdom and South Africa, and is supported by a grant from the Bill & Melinda Gates Foundation. Its focus is on combating tuberculosis, which infects one-third of the world’s population.

This project supports high-throughput screening on whole Mycobacterium tuberculosis bacteria using a chemical library of diverse, high-quality molecules. The goal is to identify a series of well-characterized small molecules with defined, tractable bacterial targets, which have the potential for development into better drugs against tuberculosis.

Dr. Clifton Barry, Chief of the Tuberculosis research of NIAID is Principal Investigator of the HIT-TB project.